These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21319287)

  • 1. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
    Wu J; Dombi E; Jousma E; Scott Dunn R; Lindquist D; Schnell BM; Kim MO; Kim A; Widemann BC; Cripe TP; Ratner N
    Pediatr Blood Cancer; 2012 Feb; 58(2):173-80. PubMed ID: 21319287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
    Ferguson MJ; Rhodes SD; Jiang L; Li X; Yuan J; Yang X; Zhang S; Vakili ST; Territo P; Hutchins G; Yang FC; Ingram DA; Clapp DW; Chen S
    Pediatr Blood Cancer; 2016 Feb; 63(2):206-13. PubMed ID: 26375012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
    Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
    Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells.
    Wu J; Williams JP; Rizvi TA; Kordich JJ; Witte D; Meijer D; Stemmer-Rachamimov AO; Cancelas JA; Ratner N
    Cancer Cell; 2008 Feb; 13(2):105-16. PubMed ID: 18242511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
    Huynh H; Lee JW; Chow PK; Ngo VC; Lew GB; Lam IW; Ong HS; Chung A; Soo KC
    Mol Cancer Ther; 2009 Jan; 8(1):152-9. PubMed ID: 19139124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
    Pécuchet N; Lebbe C; Mir O; Billemont B; Blanchet B; Franck N; Viguier M; Coriat R; Tod M; Avril MF; Goldwasser F
    Br J Cancer; 2012 Jul; 107(3):455-61. PubMed ID: 22767146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs: abatacept, sorafenib, and nelarabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2006; 46(2):300-3. PubMed ID: 16602235
    [No Abstract]   [Full Text] [Related]  

  • 12. Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma.
    Plante C; Mohamad T; Hewa Bostanthirige D; Renaud M; Sidhu H; ElChoueiry M; Vatasescu JS; Poirier M; Geha S; Brosseau JP
    PLoS One; 2024; 19(6):e0301040. PubMed ID: 38900740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
    Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
    Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
    Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
    J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and sunitinib.
    Kim A; Balis FM; Widemann BC
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
    Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
    J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
    Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
    Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus: in advanced renal cell carcinoma.
    Garnock-Jones KP; Keating GM
    Drugs; 2009 Oct; 69(15):2115-24. PubMed ID: 19791829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
    Staser K; Yang FC; Clapp DW
    Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.